Vancomycin Prevents Polytetrafluoroethylene Graft Infections in Pediatric Patients Receiving Chronic Hemodialysis

Authors

Barbara A. Fivush, School of Medicine and Health Sciences
Glenn H. Bock, School of Medicine and Health Sciences
Philip C. Guzzetta, School of Medicine and Health Sciences
Jose R. Salcedo, School of Medicine and Health Sciences
Edward J. Ruley, School of Medicine and Health Sciences

Document Type

Journal Article

Publication Date

1-1-1985

Journal

American Journal of Kidney Diseases

Volume

5

Issue

2

DOI

10.1016/S0272-6386(85)80007-X

Keywords

Hemodialysis; PTFE grafts; vancomycin

Abstract

Polytetrafluoroethylene (PTFE) grafts have been a useful addition to the pediatric hemodialysis vascular access armamentarium. In this study, 17 pediatric patients underwent 331 total months of hemodialysis via PTFE grafts. There was a statistically significant (P < .025) decrease in the incidence of graft infections in 12 patients (235 patient-months) while receiving prophylactic parenteral vancomycin compared with 9 patients (96 patient-months) while receiving no vancomycin (0% v 44%). Vancomycin side effects were uncommon and mild. Vancomycin is a safe and effective agent for the prevention of PTFE graft infections in pediatric patients receiving chronic hemodialysis. © 1985, National Kidney Foundation Inc.. All rights reserved.

APA Citation

Fivush, B., Bock, G., Guzzetta, P., Salcedo, J., & Ruley, E. (1985). Vancomycin Prevents Polytetrafluoroethylene Graft Infections in Pediatric Patients Receiving Chronic Hemodialysis. American Journal of Kidney Diseases, 5 (2). http://dx.doi.org/10.1016/S0272-6386(85)80007-X